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Abstract
Introduction: Activation of cyclooxygenase (COX)/prostaglandin and nuclear factor κB (NFκB) pathways can promote
breast tumor initiation, growth, and progression to drug resistance and metastasis. Thus, anti-inflammatory drugs have
been widely explored as chemopreventive and antineoplastic agents. Aspirin (ASA), in particular, is associated with
reduced breast cancer incidence but gastrointestinal toxicity has limited its usefulness. To improve potency and
minimize toxicity, ASA ester prodrugs have been developed, in which the carboxylic acid of ASA is masked and
ancillary pharmacophores can be incorporated. To date, the effects of ASA and ASA prodrugs have been largely
attributed to COX inhibition and reduced prostaglandin production. However, ASA has also been reported to inhibit
the NFκB pathway at very high doses. Whether ASA prodrugs can inhibit NFκB signaling remains relatively unexplored.
Methods: A library of ASA prodrugs was synthesized and screened for inhibition of NFκB activity and cancer stem-like
cell (CSC) properties, an important PGE2-and NFκB-dependent phenotype of aggressive breast cancers. Inhibition of
NFκB activity was determined by dual luciferase assay, RT-QPCR, p65 DNA binding activity and Western blots. Inhibition
of CSC properties was determined by mammosphere growth, CD44+CD24−immunophenotype and tumorigenicity at
limiting dilution.
Results: While we identified multiple ASA prodrugs that are capable of inhibiting the NFκB pathway, several were
associated with cytotoxicity. Of particular interest was GTCpFE, an ASA prodrug with fumarate as the ancillary
pharmacophore. This prodrug potently inhibits NFκB activity without innate cytotoxicity. In addition, GTCpFE exhibited
selective anti-CSC activity by reducing mammosphere growth and the CD44+CD24−immunophenotype. Moreover,
GTCpFE pre-treated cells were less tumorigenic and, when tumors did form, latency was increased and growth rate
was reduced. Structure-activity relationships for GTCpFE indicate that fumarate, within the context of an ASA prodrug,
is essential for anti-NFκB activity, whereas both the ASA and fumarate moieties contributed to attenuated
mammosphere growth.
Conclusions: These results establish GTCpFE as a prototype for novel ASA-and fumarate-based anti-inflammatory
drugs that: (i) are capable of targeting CSCs, and (ii) may be developed as chemopreventive or therapeutic agents in
breast cancer.
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Background
Inflammation is a well-established cancer risk factor that
affects incidence, promotion, and progression and is
widely associated with an overall poor patient outcome
[1, 2]. In breast cancer, epidemiological studies report an
inverse association between the use of non-steroidal
anti-inflammatory drugs (NSAIDs) and breast cancer
risk [3–5]. In particular, regular use of the classical
NSAID, aspirin (acetylsalicylic acid, ASA), leads to a re-
duction in breast cancer incidence [6–9]. Although there
is a general consensus on the benefits of aspirin use, a
limited number of studies, such as the study by Cook et
al. [10], reported no such benefits. These inconsistencies
may be reconciled if aspirin dose, duration, and study
design are taken into consideration. The anti-cancer ef-
fects of ASA are primarily attributed to its ability to in-
hibit cyclooxygenase 2 (COX2) activity, which is often
up-regulated in breast cancer [11, 12], and reduce pro-
duction of prostaglandin E2 (PGE2), the predominant
secreted prostaglandin in breast tumors [13]. A number
of studies suggest that ASA may also act, at least in part,
by suppressing aberrant nuclear factor κB (NFκB) signal-
ing [14–18]. This activity would be desirable in breast
cancer since NFκB can promote tumor cell survival, pro-
liferation, migration, invasion, angiogenesis, and resist-
ance to therapy [19–21].
More recently, both the COX2/PGE2 axis and the
NFκB signaling pathway have been implicated in the sur-
vival and propagation of breast cancer stem cells (CSCs)
[22–28]. According to the CSC hypothesis, breast CSCs
are a subset of cells within the tumor that can self-
renew, differentiate, and evade anoikis [29–31]. CSCs
are also highly tumorigenic, therapy resistant, and in-
volved in metastasis and tumor recurrence [32–37].
Therefore, it is thought that successfully targeting breast
CSCs may sensitize resistant tumors to therapy and pre-
vent future recurrence and metastasis. Moreover, it is
plausible that anti-inflammatory drugs that simultan-
eously target both the COX2/PGE2 and NFκB pathways,
such as ASA, can be exploited to eradicate CSCs.
Unfortunately, the use of ASA to achieve COX2 and
NFκB inhibition is associated with gastrointestinal (GI)
toxicity [38]. Even at the lowest dose of daily use
(81 mg/baby aspirin), ulcers and stomach bleeding occur
and exemplify the limitations of extended ASA use [39].
For NFκB inhibition, the problem is compounded fur-
ther by the low potency of ASA on this pathway. For
example, the lowest reported IC50 for inhibition of IKKβ,
a key kinase in the NFκB pathway, by ASA is 80 μM on
purified protein in vitro [15]. In cells or animal models,
the dose of ASA required to inhibit NFκB is a thousand-
fold higher [14–18]. To overcome GI toxicity, ASA pro-
drugs have been developed, validated in animal models,
and advanced to clinical trials [40–44]. The prodrug
strategy consists of converting ASA into an ester pro-
drug, thereby introducing lipophilicity into the molecule
and masking the carboxylate’s hydrogen bonding groups.
In turn, this enhances cellular uptake and permeability
of ASA prodrugs. The resulting enhanced potency allows
for reduced doses, which then minimizes GI toxicity. To
further enhance potency and/or add functionality, design
of prodrugs may also incorporate other structural ele-
ments or ancillary pharmacophores.
While ASA prodrugs have been studied as COX inhib-
itors, their specific activity on the NFκB pathway in
breast cancer remains relatively unexplored [45, 46]. To
address this, we synthesized a series of ASA ester pro-
drug pairs that incorporate ancillary pharmacophores,
some with proven anti-inflammatory activity, in either
para (p) or meta (m) position (Fig. 1a) [47–53]. The ob-
jective was to identify prodrugs with enhanced potency
for NFκB inhibition, reduced cytotoxicity, and selective
targeting of breast CSCs, which together would indicate
a favorable therapeutic index. While several of these
ASA prodrugs are potent NFκB inhibitors, they are also
cytotoxic. In contrast, GTCpFE, a fumarate-based ASA
prodrug, is an effective NFκB inhibitor without any con-
comitant cytotoxicity. Moreover, GTCpFE can effectively
target breast CSCs by simultaneously inhibiting both
COX and NFκB pathways. As a consequence, this
prodrug strategy lays the groundwork for future anti-
inflammatory and anti-CSC drug development.
Methods
Reagents
TNFα and IL-1β were purchased from R&D Systems.
ASA was purchased from Sigma. IKKVII was purchased
from EMD Millipore. Antibodies for p-IKKα/β (#2697),
IKKα (#2682), IKKβ (#2370), p-IκBα (#2859), IκBα
(#4814) and p-p65 (S536, #3033) were purchased from
Cell Signaling. The antibody for p65 (sc-372) was pur-
chased from Santa Cruz and β-actin (A5441) from
Sigma.
ASA prodrugs synthesis
GTpBr, GTmBr, and ASApASA were synthesized as previ-
ously reported [42, 47]. ASAmASA, GTCpFE, GTCmFE,
GTSp304, GTSm304, BzFE, and GTCpSE were synthe-
sized, purified, and fully characterized as described in the
Additional file 1: Supplementary Methods and Additional
file 2: Figure S1.
Cell lines and culture conditions
Well characterized human cell lines that are genetically
and phenotypically different but represent major breast
cancer subtypes were used for these studies. For the
luminal estrogen receptor (ER) + subtype, we utilized
MCF-7 and T47D cells, which express high levels of ER
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and proliferate in response to estrogen treatment. For
the HER2 subtype, we utilized BT474 cells, which over-
express the oncogene epidermal growth factor receptor
2 (Her2). For the triple negative subtype, we utilized
MDA-MB-231 cells, which are basal/mesenchymal cell
types, and lack expression of ER, PR and Her2. MCF-7,
T47D, and BT474 cells were obtained from Dr. Debra
Tonetti (University of Illinois at Chicago). These cells
were routinely maintained in RPMI 1640 media (Invitro-
gen Life Technologies) with phenol red supplemented
with 10 % FBS, 1 % non-essential amino acids, 2 mmol/
L L-glutamine, 1 % antibiotics penicillin-streptomycin,
and 6 ng/mL insulin. MDA-MB-231 cells were obtained
from Dr. Clodia Osipo (Loyola University Chicago) and
routinely maintained in IMEM media (Corning) supple-
mented with 5 % FBS, 1 % non-essential amino acids,
2 mM L-glutamine, and 1 % antibiotics penicillin-
streptomycin.
Luciferase reporter assay
MCF-7 cells were transiently co-transfected with an
NFκB-RE luciferase construct (Clontech) along with the
renilla luciferase construct, pGL4.70 (Promega), and dual
luciferase assays were carried out as previously described
[54].
RT-quantitative PCR (QPCR)
Total RNA was isolated using the Trizol method, then
reverse transcribed (RT), and analyzed by QPCR per-
formed as previously described [55]. Fold change was
calculated using the ΔΔCt method with 36B4 serving as
the internal control. QPCR primer sequences are avail-
able upon request.
p65 DNA binding assay
Nuclear extracts were isolated and p65 DNA binding
activity was measured via an ELISA (Active Motif )
according to manufacturer’s guidelines.
Western blot
Whole cell extracts were prepared using the M-PER
reagent (Thermo Scientific). Proteins were separated by
SDS-PAGE (Bio-Rad Laboratories), transferred to nitro-
cellulose membranes (Thermo Scientific), blocked for
1 hour in buffer containing 5 % nonfat dry milk (Lab
Scientific) or 5 % bovine serum albumin, and incubated
Fig. 1 ASA prodrugs inhibit NFκB activity in breast cancer cells. a Chemical structures of ASA prodrugs are indicated. Four ancillary pharmacophores,
bromide (Br), acetylsalicylate (ASA), fumarate (FE), or sulfonate (S), were incorporated in either para (p) or meta (m) position. b-e MCF-7 cells were
pretreated for 2 hours with 1 μM of IKKVII, 50 μM of ASA, 50 μM of ASA prodrugs, or vehicle (Veh) followed by treatment with TNFα (10 ng/ml) for
2 hours. b NFκB-RE activity was measured by dual luciferase reporter assay after TNFα (10 ng/ml) for 4 hours. (c-e) Expression of NFκB target genes,
ICAM1, TNF and CCL2 was measured by RT-QPCR. Drug inhibitory activity is plotted as % of TNFα alone. Data points with different letters (a, b, c) are
significantly different from one another, P < 0.05
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with the appropriate primary antibody overnight. The
next day, secondary antibody was applied and the signal
was visualized on a Molecular Imager ChemidocXRS
(Bio-Rad Laboratories) using the Pierce Supersignal
West Pico chemiluminescent substrate (Thermo Scien-
tific). Images were obtained using Quantity One software
(Bio-Rad Laboratories).
MTS viability assay
Cell viability upon drug treatment was measured via the
CellTiter96® AQueous One Solution assay (Promega).
Mammosphere (MS) assay
Breast cancer cells were seeded at single cell density on
low attachment plates in media described by Dontu et
al., supplemented with 1 % methyl cellulose to prevent
cellular aggregation [29]. After 7 days, the diameter of
MS was measured and MS ≥75 μm in diameter were
counted. For MS formation studies, inhibitors were
added the day after seeding. For RNA, p65 DNA binding
activity, and protein studies, MS were grown for 7 days
and inhibitors were added for the last 3–6 hours.
PGE2 assay
For measuring secreted PGE2, conditioned media was
collected after 24 hours of treatment and a PGE2 ELISA
(R&D Systems) was run according to the manufacturer’s
specifications.
CSC immunophenotype
Antibodies for CD44 and CD24 were purchased from
Pharmingen. Cell labeling and flow cytometry was done
according to Liu et al. [56].
Tumorigenicity in athymic mice
All mouse experiments were carried out at the University
of Illinois at Chicago animal facility. All mouse experi-
ments were conducted in accordance with institutional
procedures and guidelines, and prior approval from the
Institutional Animal Care and Use Committee. Female
athymic nude mice (nu/nu), aged 4–5 week-old, were pur-
chased from Harlan. Following 72 hour pretreatment with
DMSO vehicle (Veh) or GTCpFE, one million MDA-MB-
231 cells were injected orthotopically into the thoracic
mammary glands (N = 8 injections per group). Tumor
formation was monitored by palpitation and day 1 was
considered the first day a tumor was observed. Tumor size
was then measured 3 times per week with an electronic
caliper.
Statistical analysis
Data are presented as mean ± SEM from at least three
independent determinations. Statistical analysis consisted
of 1- or 2-way ANOVA followed by Tukey posttest, or t
test, as appropriate.
Results
Anti-NFκB activity of aspirin prodrugs in breast cancer
cells
To determine whether the ASA prodrugs we synthesized
(Fig. 1a and Additional file 2: Figure S1) inhibit the
NFκB pathway, their activity was screened in MCF-7
breast cancer cells at one dose (50 μM) on NFκB-RE
and NFκB target gene endpoints (Fig. 1b-e). The pro-
inflammatory cytokine, TNFα, was used to activate the
NFκB pathway and IKKVII, a known IKKα/β inhibitor,
was used as a positive control. We find that the ASA
prodrugs incorporating bromide, acetyl salicylate, and
fumarate but not sulfonate or ASA itself, significantly
inhibit both NFκB-RE activity and NFκB target genes,
including ICAM1, CCL2, and TNF. To determine the
therapeutic potential of these ASA prodrugs, we next
examined whether they were cytotoxic. Both the brom-
ide and acetylsalicylate analogs significantly reduce cell
viability of MCF-7 cells and a second breast cancer cell
line, BT474 (Fig. 2). However, the known NFκB inhibitor,
IKKVII, or ASA itself do not show the same effect on
cell viability. This suggests that the bromide and acetyl
salicylate prodrugs, besides NFκB inhibition, display add-
itional off-target activity. Therefore, the bromide and
acetyl salicylate prodrugs were withdrawn from further
consideration. This, in combination with sulfonates’
poor NFκB pathway inhibition, led to the fumarate pair
emerging as the best candidates, and GTCpFE was
selected as a prototype for further detailed study.
Dose response studies were conducted in MCF-7 cells
and GTCpFE was found to inhibit both NFκB-RE activ-
ity and expression of NFκB target genes, such as
ICAM1, CCL2 and TNF, with a calculated IC50 value of
~20 μM (Fig. 3a, b). In addition, GTCpFE was found to
inhibit NFκB activity in other breast cancer cell lines,
such as BT474 and MDA-MB-231 (Fig. 3e, f ), and in
response to other cytokines, including IL-1β (Additional
file 3: Figure S2). In contrast, ASA alone had no effect
on NFκB-RE activity and expression of target genes in
breast cancer cells even at doses as high as 200 μM
(Fig. 4a-c).
The canonical NFκB pathway consists of p65 and p50
transcription factors, which are held in the cytoplasm by
an inhibitor protein, IκBα. Upon stimulation by inflam-
matory cytokines (such as TNFα, IL-1β) or other factors,
the IκB kinase (IKK) complex is activated, leading to
phosphorylation and degradation of IκBα. As a result,
p65/p50 factors are liberated and can translocate to the
nucleus, where they bind to DNA. To determine where
in this pathway GTCpFE may be acting, we first exam-
ined DNA binding activity of the NFκB family member,
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p65 (RelA). GTCpFE inhibits p65 DNA binding by ~50 %,
which is comparable in this assay to the known IKKα/β
inhibitor, IKKVII (Fig. 3c). We next examined upstream
components in the NFκB signaling pathway and found
that IKKα/β phosphorylation, IκBα phosphorylation and
degradation, and p65 phosphorylation were impaired by
GTCpFE (Fig. 3d). These data indicate that GTCpFE, but
not ASA (Fig. 4d), is capable of inhibiting NFκB activity in
breast cancer cells, by blocking IKKα/β phosphorylation
and subsequent activation of the p65 transcription factor.
Thus, GTCpFE represents a significant improvement
compared to ASA on NFκB pathway inhibition.
GTCpFE inhibits breast cancer stem cell properties
Because the breast CSC phenotype has been shown to
dependent on both COX2/PGE2 [25–28] and NFκB
activity [22–24], we next explored whether GTCpFE could
affect formation of mammospheres (MS), which are
enriched for cells with the stem-like properties of self-
renewal and anchorage-independent growth [29, 30].
GTCpFE prevented MS formation in a dose-dependent
manner in all breast cancer cell lines examined (Fig. 5a).
Importantly, MS inhibition occurred at doses that do not
affect cell viability in standard adherent monolayer cul-
tures (Fig. 5a). To determine if GTCpFE can affect the
NFκB pathway or PGE2 production in breast CSCs, MS
were allowed to form over 7 days and inhibitors were
added for the last 3–24 hours of culture. MS displayed
elevated levels of p65 DNA binding, NFκB target gene
expression, and p65 phosphorylation compared to un-
treated breast cancer cells cultured in standard monolayer
(2D) conditions. All of these endpoints were attenuated by
Fig. 2 Effect of ASA prodrugs on cell viability. a-d MCF-7 (A, C) or BT474 (B, D) cell viability using the MTS assay was measured after 24 or 48 hours
of treatment with 1 μM of IKKVII, 10 μM of ASA or 10 μM of ASA prodrugs. Drug activity is plotted as % of DMSO vehicle control. Stars above
indicate significance compared to control, * P < 0.05, ** P < 0.01, *** P < 0.001. e Representative pictures of MCF-7 cells after 24 hours treated with
increasing concentrations of ASApASA indicate an abnormal cell phenotype
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GTCpFE (Fig. 5b-e). Also, PGE2 production is reduced in
MS treated with GTCpFE, confirming the expected ASA-
like activity (Fig. 5f). Together, these findings suggest that
GTCpFE can block MS formation by inhibiting both the
NFκB pathway and PGE2 production.
We next conducted follow-up studies to confirm that
GTCpFE is in fact targeting breast CSCs. For these stud-
ies, MDA-MD-231 cells were selected since they have
previously been shown to contain a higher percentage of
CSCs [57, 58], given their mesenchymal character [59].
MDA-MB-231 cells were pre-treated for 72 hours with
GTCpFE, followed by washing and measurement of
three well-established CSC endpoints: CD44+CD24− cell
surface marker expression, MS formation, and xenograft
tumor initiation. GTCpFE pre-treatment resulted in a
significant depletion of the CD44+CD24− population
(Fig. 6a). Similarly, consistent with the depletion of
CSCs, we observe that GTCpFE pre-treated cells are
functionally less capable of MS formation, even in the
absence of continued GTCpFE treatment (Fig. 6b).
Fig. 3 GTCpFE inhibits TNFα-induced NFκB signaling. a TNFα-induced NFκB-RE activity and b NFκB target gene expression was measured in
MCF-7 cells pretreated with increasing concentrations of GTCpFE. IC50s were calculated using GraphPad software. c p65 DNA binding activity was
measured in MCF-7 cells treated IKKVII (1 μM) or GTCpFE (50 μM) for 2 hours, followed by TNFα treatment for 15 minutes. The different letters
above bars indicate significant difference between treatments (P < 0.001). d Whole cell extracts of cells treated as in (C) were prepared and NFκB
signaling proteins were examined by western blotting. Representative western blots from three independent experiments are shown. β-actin
served as a loading control. e-f TNFα-induced expression of ICAM1, CCL2 and TNF in (E) BT474 or (F) MDA-MB-231 cells was measured after
pretreatment with varying concentrations of GTCpFE
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The “gold standard” for assaying anti-CSC properties
is in vivo tumorigenicity, wherein the ability of drug-
treated cells to initiate or seed a xenograft tumor is
examined [60, 61]. Because CSCs are the population
present in each cell line capable of tumorigenicity, a
drug that attenuates this population, is reflected in re-
duced tumor initiation capacity or incidence. MDA-MB-
231 cells were treated with GTCpFE (50 μM or 100 μM)
for 72 hours, followed by washing and injection into the
mammary fat pad of female athymic nude mice.
GTCpFE at 100 μM decreased the overall number of
tumors that formed (Fig. 6c, left). Furthermore, of the
tumors that did form from GTCpFE pre-treated cells,
latency was increased (Fig. 6c, left), and the growth rate
was significantly reduced (Fig. 6c, right). Altogether,
these data confirm that the novel anti-inflammatory
agent, GTCpFE, is also a potent anti-CSC agent.
Structural components of GTCpFE necessary for anti-NFκB
and anti-CSC activity
Since GTCpFE inhibits the NFκB pathway and PGE2
production, and is capable of attenuating breast CSCs
without non-specific toxicity, we next examined what
components of its structure contribute to its activity. A
series of compounds with truncated or inactivated
moieties were tested (Fig. 7a). For anti-NFκB activity,
the fumarate group appears to be essential since
GTCmFE, the meta isomer of GTCpFE, retains its in-
hibitory function (Fig. 7b, c). Also, BzFE, which lacks the
ASA moiety but retains the fumarate, inhibits the NFκB
pathway in a similar manner to GTCpFE (Fig. 7b, c).
Furthermore, GTCpSE, which consists of ASA linked to
succinate, a structural analog of fumarate that lacks the
reactive double bond, is not capable of inhibiting the
NFκB pathway (Fig. 7b, c). These findings indicate that
the fumarate component of GTCpFE is necessary to
elicit the observed inhibition of the NFκB pathway in
breast cancer cell lines. Interestingly, when we tested the
hydrolysis products of GTCpFE – ASA and monoethyl
fumarate (MEF), either alone or in combination – no
effect was observed (Fig. 7b, c). This implies that fumar-
ate within an intact prodrug is required for the anti-
inflammatory activity of GTCpFE on the NFκB pathway.
For anti-CSC activity of GTCpFE, both the fumarate and
the ASA moieties are required. An ASA prodrug with inac-
tivated fumarate, GTCpSE, has no effect on MS growth
(Fig. 7d), suggesting the fumarate is required. However, the
fumarate alone is not sufficient, because the analog lacking
the ASA moiety, BzFE, has little effect on MS formation
(Fig. 7d). We also tested IKKVII for its effect on the CD44
Fig. 4 ASA cannot inhibit NFκB activity in breast cancer cells. a NFκB-RE activity or b NFκB target gene expression (ICAM1, CCL2 and TNF) was
measured in MCF-7 cells treated with different concentrations of ASA. c RT-QPCR for NFκB target gene expression was measured in MDA-MB-231
cells treated with increasing concentrations of ASA. TNFα was used to activate NFκB, and ASA response is plotted as % of TNFα alone. d ASA
cannot inhibit TNFα induced phosphorylation of IKKs. MCF-7 cells were pretreated with 50 μM GTCpFE or ASA for 2 hours followed by TNFα for
15 minutes. Phosphorylated and total IKK levels were examined by western blotting. β-actin served as a loading control
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+CD24− immunophenotype Additional file 4: Figure S3),
and found that it modestly attenuates the CD44+CD24−
population compared to GTCpFE (Figure 6a). This suggests
that NFκB inhibition, whether by fumarates or IKKVII, is
only partially effective on CSCs. Similarly, the ASA moiety
alone is not sufficient, because ASA has no effect. This in
addition to GTCpSE data indicates that simple COX inhib-
ition is not sufficient either. Altogether, these findings
suggest that both the anti-NFκB and anti-COX activity of
GTCpFE are required for its superior anti-CSC effect.
Discussion
In this study, we have demonstrated that ASA prodrugs
with ancillary pharmacophores can be effectively used to
inhibit NFκB activity in breast cancer cells, whereas ASA
itself was ineffective at much higher concentrations. While
we hypothesized that prodrug isomerism (para vs meta)
would be important [47], our data indicate that in fact
pharmacophore reactivity is the main driver of biological
activity. For instance, we find several highly reactivity
pharmacophores, but they also display inherent cytotox-
icity. Instead, incorporation of the fumarate pharmaco-
phore, as in GTCpFE, proved to be the optimal moiety in
balancing potent anti-NFκB activity versus no concomi-
tant cytotoxicity. We find GTCpFE to effectively inhibit
NFκB activation in a breast cancer subtype-independent
manner demonstrated in multiple breast cancer cell lines
and the intrinsic NFκB activity essential for CSCs.
Fig. 5 The effects of GTCpFE in MS culture of breast cancer cells. a MS formation and cell viability from indicated cell lines was measured after
treatment with varying concentrations of GTCpFE. The effect of GTCpFE in both assays is plotted as % of DMSO vehicle control. b p65 DNA
binding activity was measured in conventional adherent 2D culture of MCF-7 cells or MS culture with or without inhibitors (IKKVII 1 μM or GTCpFE
50 μM) added for the last 3 hours. c-d TNF (C) and CCL2 (D) expression after 6 hours was measured in treatment groups described in (B). The
different letters (a, b, c) above bars indicate significant difference between treatments, P < 0.05. e Total and p-p65 levels are measured in 2D vs
MS culture treated with 50 μM GTCpFE. f PGE2 levels in the media of MDA-MB-231 MS was measured upon treatment with 20 μM GTCpFE for
24 hours, * P < 0.05
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Interestingly, the fumarate alone is not sufficient to in-
hibit NFκB but that its presence within the intact pro-
drug is required. The activity of GTCpFE was not seen
in an analogue, GTCpSE, identical except for the pres-
ence of the fumarate structural element, and therefore,
is ascribed to the fumarate pharmacophore, designed to
enhance anti-NFκB activity. However, the finding that
MEF, either alone or in combination with ASA had no
effect suggests that fumarate alone is not sufficient to
inhibit NFκB but required as part of the prodrug. Like-
wise, the simple ASA prodrug approach is not sufficient
to inhibit NFκB. Innumerable studies have shown that in
cell culture, ASA itself has very low potency, whereas
cell-permeable ester prodrugs are dramatically more po-
tent as anti-inflammatory or anti-cancer agents. Accord-
ingly, GTCpSE was designed as an ASA ester prodrug,
identical to GTCpFE in all aspects but the fumarate, yet
it shows no activity against the NFκB pathway. Together
these observations demonstrate the importance of the
fumarate pharmacophore and show that the anti-NFκB
activity of GTCpFE goes beyond that of a simple ASA
ester prodrug.
Fig. 6 GTCpFE pre-treatment reduces the CD44+CD24− population, MS growth, and tumor initiation capacity. a The CD44+CD24− population was
determined by FACS analysis of MDA-MB-231 cells treated with 50 μM GTCpFE for 72 hours. Quantitation of each population percentage (left) and
representative scatter plots from FACS (right) are shown. *** P < 0.001. b MS formation was measured following pretreatment of MDA-MB-231 cells
with 50 or 100 μM GTCpFE for 72 hours. GTCpFE is then withdrawn prior to seeding in MS culture. MS growth inhibition was plotted as % of DMSO
vehicle control (left) and representative pictures of MS growth are shown (10×, right). *** P < 0.001; ND, none detected. c The number of xenograft
tumors initiated over time (left panel) and their growth rates (right panel) was determined from GTCpFE or vehicle pre-treated MDA-MB-231 cells.
* P < 0.05, ** P < 0.01
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Use of fumarates as anti-inflammatory agents is not un-
precedented; dimethyl fumarate (Tecfidera®) is an approved
anti-inflammatory drug that has been shown to inhibit
NFκB signaling in a variety of cell lines [49–53]. The mech-
anism by which dimethyl fumarate inhibits the NFκB path-
way is unclear but does not appear to involve the upstream
IKKs. Rather, nuclear entry and phosphorylation of NFκB
transcription factors is attenuated and other kinases such as
MSK-1 appear to be involved [50, 53]. In contrast, our stud-
ies demonstrate that GTCpFE inhibits IKKα/β activity and
subsequent activation of the p65 transcription factor. This
may be a new mode of action for this particular ASA pro-
drug that extends beyond that of the parent drug.
Our findings suggest that GTCpFE may also be a promis-
ing, clinically relevant anti-inflammatory molecule for
eradication of breast CSCs by exploiting CSC’s reliance on
multiple inflammatory pathways [22–26]. GTCpFE, at con-
centrations where MS formation is completely abrogated,
showed little to no effect on viability of adherent parental
cells. In addition, the promising in vitro anti-CSC proper-
ties of GTCpFE translated to attenuated tumorigenicity of
MDA-MB-231 xenografts compatible with the diminution
of the CSC population by GTCpFE. Interestingly, inhibition
of CSCs requires both the anti-NFκB activity and retention
of ASA-like activity on COX-PGE2 axis. Testing whether
these findings on the anti-CSC activity of GTCpFE in a
xenograft model also translate in an immunocompetent
transgenic mouse model of breast cancer would be of great
interest and subject to future studies.
Targeting breast CSCs, which are at the apex of the tumor
hierarchy, is increasingly recognized as fundamental to ef-
fective anti-cancer therapy. Breast CSCs, also referred to as
tumor-initiating cells, are highly tumorigenic, can evade
anoikis, and are capable of self-renewal and asymmetrical
division; and thereby can reconstitute intratumoral hetero-
geneity [29–31]. Breast CSCs were shown to be resistant to
treatment with chemotherapeutics and ionizing radiation
[33, 34]. They also display epithelial-mesenchymal transition
features, and thus are thought to mediate tumor metastasis
and tumor recurrence [36, 37]. These properties of breast
CSCs negatively impact clinical outcome, highlighting the
need for new therapeutic strategies to target CSCs. Cur-
rently, standard therapeutic drugs are seen as ineffective in
killing CSCs and no specific CSC agents have been
approved.
Conclusion
Based on our studies, we conclude that the fumarate-
based ASA prodrug, GTCpFE, described herein, is a
prototype for developing new anti-inflammatory and
anti-CSC class of drugs with the potential to impact
aggressive breast cancers.
Fig. 7 The fumarate moiety of GTCpFE is required for the NFκB inhibition in breast cancer cells. a Structural analogs of GTCpFE are indicated.
b NFκB-RE activity was measured in MCF-7 cells following treatment with TNFα and the analogs shown in (A) 20 μM each. c RT-QPCR for ICAM1
gene expression was measured in MCF-7 cells treated as in (B). d MS formation of MCF-7 cells treated with 20 μM GTCpFE, ASA, BzFE, and GTCpSE
demonstrate attenuated MS growth. Quantitation of MS growth (left panel) and representative pictures (20×) of MS (right panel) are shown. The
different letters above bars (a, b, c) indicate significant difference between treatments, P < 0.05
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Additional files
Additional file 1: Supplemental Methods. Synthetic procedures and
characterization of chemicals used are indicated. (PDF 762 kb)
Additional file 2: Figure S1. Synthesis of ASA prodrugs. Chemical
structures and synthetic schemes are indicated and described in
Additional file 1: Supplemental Methods. (PPTX 133 kb)
Additional file 3: Figure S2. GTCpFE inhibits cytokine-induced NFκB
target gene expression in breast cancer cells. MCF-7 cells were pretreated
for 2 hours with increasing concentrations of GTCpFE followed by treatment
with IL-1β (10 ng/ml) for another 2 hours. Expression of NFκB target genes,
ICAM1 and CCL2 was measured by RT-QPCR. Drug inhibitory activity is
plotted as % of IL-1β alone. (PPTX 72 kb)
Additional file 4: Figure S3. The effect of NFκB inhibitor, IKKVII, on the
CD44+CD24− population. The CD44+CD24− population percentage was
determined by FACS analysis of MDA-MB-231 cells treated with 2.5 μM
IKKVII for 72 hours. * P < 0.05. (PPTX 48 kb)
Abbreviations
ASA: acetylsalicylic acid, aspirin; COX: cyclooxygenase; CSC: cancer stem cell;
MS: mammosphere; NFκB: nuclear factor κB; NSAID: non-steroidal
anti-inflammatory drug; PG: prostaglandin.
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